On the other, GAPs like RASA3 are potentially druggable and our proof‐of‐concept study provides evidence that inhibition of RASA3 GAP activity can significantly reduce metastasis of breast cancer irrespective of the subtype and likely even in other cancer types. This evidence concerns the gene RASA3 and breast carcinoma.